Summary Highlights:
- Axsome Therapeutics beats earnings expectations with a Q1 GAAP EPS of -$1.22.
- Revenue soars with a 62% year-over-year increase, reaching $121.46 million.
- Strong financial footing with cash reserves of $300.9 million, poised for cash flow positivity.
Axsome Therapeutics: Earnings Beat Expectations
Axsome Therapeutics (AXSM, Financial) has reported a Q1 GAAP EPS of -$1.22, exceeding market expectations by $0.13. This positive surprise comes on the back of robust revenue growth, with the company's revenue climbing to $121.46 million—a remarkable 62% increase compared to the previous year. This performance surpassed the forecast by $2.22 million. The firm demonstrates strong liquidity, boasting cash reserves of $300.9 million, and is well-positioned to reach cash flow positivity.
Wall Street Analysts' Projections
According to 17 analysts, Axsome Therapeutics Inc (AXSM, Financial) has an average one-year price target of $176.76, with estimates ranging from a high of $210.00 to a low of $143.00. This average price target suggests a potential upside of 57.53% from the current share price of $112.21. To explore more specific estimate data, visit the Axsome Therapeutics Inc (AXSM) Forecast page.
The consensus from 18 brokerage firms rates Axsome Therapeutics Inc (AXSM, Financial) with an average brokerage recommendation of 1.7, which corresponds to an "Outperform" rating. The brokerage rating scale ranges from 1 (Strong Buy) to 5 (Sell).
GuruFocus Valuation Insights
According to GuruFocus estimates, the GF Value for Axsome Therapeutics Inc (AXSM, Financial) in one year is projected to be $262.18. This estimate suggests a substantial upside of 133.65% from the current price of $112.21. The GF Value represents GuruFocus's assessment of the fair trading value for the stock, derived from historical trading multiples and expected future business performance. Further detailed information can be accessed on the Axsome Therapeutics Inc (AXSM) Summary page.
Investors should consider these insights as part of their informed decision-making process when evaluating the potential of Axsome Therapeutics Inc (AXSM, Financial) as a viable investment opportunity.
